Eli Lilly’s retatrutide program is drawing attention not only for its clinical promise but also for how access is being handled before regulatory clearance. According to STAT+, Lilly and the FDA granted compassionate use access to one individual, underscoring the intensity of demand around next-generation obesity candidates. Separately, hospitals have raised objections to Lilly’s 340B compliance approach after the company followed an ultimatum to stop paying 340B discounts unless hospitals submitted new paperwork. Hospital groups urged federal regulators to intervene, arguing Lilly lacks authority to impose its own compliance requirements for a federal program. The juxtaposition of compassionate-use demand and heightened payment friction illustrates how obesity drug rollouts are colliding with both regulatory access rules and reimbursement compliance dynamics. For manufacturers and payers, these developments reinforce that commercial execution involves more than clinical outcomes—pricing programs, access pathways, and administrative compliance can move quickly and unpredictably.